There is growing concern among some type 2 diabetes patients over challenges in obtaining reimbursement for medications like Novo Nordisk A/S's (NYSE: NVO) Ozempic amid stricter health plan management by U.S. insurers.
According to reports from various patients, restrictions imposed by insurers are making it harder for doctors to prescribe these medications, particularly for weight loss purposes.
In a sample group of 24 diabetes patients contacted via Reddit, 13 reported encountering recent difficulties with their health plans covering medications like Ozempic ...